nad has been researched along with olaparib in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 3 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bohr, VA; Bollineni, RC; Croteau, DL; Fang, EF; Iser, WB; Kalyanasundaram, S; Kassahun, H; Kerr, JS; Li, J; Lu, H; Lu, Q; Marosi, K; Mattson, MP; Morevati, M; Nilsen, H; Scheibye-Knudsen, M; Shamanna, RA; Sinclair, DA; Tian, J; Waltz, TB; Wilson, MA; Wollman, BN | 1 |
Auwerx, J; Bai, P; Boulares, AH; Cao, Z; Gao, B; Gariani, K; Godlewski, G; Haskó, G; Holovac, E; Horváth, B; Liaudet, L; Mukhopadhyay, P; Nemeth, BT; Pacher, P; Paloczi, J; Park, O; Persidsky, Y; Rajesh, M; Ryu, D; Varga, ZV; Wang, W; Xu, MJ; Zhou, Z | 1 |
Baks-Te Bulte, L; Brundel, BJJM; de Groot, NMS; de Vries, AAF; Henning, RH; Hoogstra-Berends, F; Hu, X; Lanters, EAH; Li, J; Liu, J; Malik, NU; Pijnappels, DA; Tolouee, M; van Marion, DMS; van Roon, AM; Wiersma, M; Zhang, D | 1 |
Hwang, Y; Jang, KH; Kim, E | 1 |
Dar'in, D; Gureev, M; Kasatkina, M; Krasavin, M; Safrygin, A; Silonov, S; Zhmurov, P; Zonis, Y | 1 |
Brunialti, MKC; Koh, IHJ; Liberatore, AMA; Martins, V; Rodrigues, LOCP; Salomão, R; Santos, SS; Soriano, FG; Szabo, C | 1 |
6 other study(ies) available for nad and olaparib
Article | Year |
---|---|
NAD
Topics: Animals; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Behavior, Animal; Caenorhabditis elegans; Cells, Cultured; Disease Models, Animal; DNA Repair; Gene Knockdown Techniques; Health; Homeostasis; Longevity; Metabolomics; Mice; Mitophagy; NAD; Neurons; Phenotype; Phthalazines; Piperazines; Proteomics; Rats, Sprague-Dawley; Signal Transduction; Sirtuin 1 | 2016 |
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Fatty Liver, Alcoholic; Humans; Kupffer Cells; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NAD; Nitrosative Stress; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phenanthrenes; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinolines; Sirtuin 1 | 2017 |
DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD
Topics: Animals; Atrial Fibrillation; Benzimidazoles; Cells, Cultured; DNA Damage; Drosophila melanogaster; Enzyme Activation; Heart Atria; Humans; Larva; Mice; Models, Cardiovascular; Myocardial Contraction; Myocytes, Cardiac; NAD; Niacinamide; Oxidative Stress; Pacemaker, Artificial; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Pupa; Rats; Rats, Wistar | 2019 |
PARP1 Impedes SIRT1-Mediated Autophagy during Degeneration of the Retinal Pigment Epithelium under Oxidative Stress.
Topics: Animals; Autophagy; Disease Models, Animal; Humans; Hydrogen Peroxide; Iodates; Lysosomes; Macular Degeneration; Male; Mice; Mice, Inbred C57BL; Mitochondria; NAD; Oxidative Stress; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Retina; Retinal Pigment Epithelium; Sirtuin 1; Wortmannin | 2020 |
Three-component Castagnoli-Cushman reaction with ammonium acetate delivers 2-unsubstituted isoquinol-1-ones as potent inhibitors of poly(ADP-ribose) polymerase (PARP).
Topics: Acetates; Amino Acid Sequence; Antineoplastic Agents; Binding Sites; DNA Damage; Drug Screening Assays, Antitumor; Humans; NAD; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Conformation; Quinolones; Structure-Activity Relationship | 2021 |
Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress.
Topics: Adenosine Triphosphate; Escherichia coli; Humans; Hydrogen Peroxide; Leukocytes, Mononuclear; Lipopolysaccharides; NAD; Oxidative Stress; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2022 |